Aligos Therapeutics Shares Jump 16% on $25M China Hepatitis B Deal
ALGS•Aligos Therapeutics shares surged 16% in after-hours trading following a $25 million upfront payment from a China licensing deal for its hepatitis B therapy. The agreement grants Greater China development and commercialization rights, extending Aligos’ cash runway and supporting ongoing clinical trials.
1. China Licensing Deal and Upfront Payment
Aligos entered into a licensing agreement with a Chinese partner, receiving a $25 million upfront payment in exchange for development and commercialization rights to its hepatitis B therapy in Greater China.
2. After-Hours Stock Surge
Shares of Aligos jumped 16% in after-hours trading as investors reacted positively to the cash infusion and the expanded market opportunity for the company’s lead HBV candidate.
3. Impact on Development and Cash Runway
The $25 million boost is expected to extend Aligos’ cash runway by roughly 12 months, funding ongoing Phase II trials and reducing near-term dilution risk.
